ClinicalTrials.gov
public full text
Public Domain
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- GT719 Injection for Moderate to Severe Refractory Autoimmune Disease#907519
- Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects#1113623
- The Clinical Study on the Treatment of SSc With UTAA91 Injection.#915628
- Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases#853824
- Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases#1047840
Record · ID 1164051
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive